Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence

References

• Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998;97(6):596–601.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. WHO publishes definitive atlas on global heart disease and stroke epidemic. Indian J Med Sci. 2004;58(9):405–406.
   Google Scholar
• Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med. 1971;74(1):1–12.
   PubMed Web of Science ®Google Scholar
• Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1(7897):16–19.
   PubMed Web of Science ®Google Scholar
• Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823–2828.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest. 1973;52(7):1533–1543.
   Web of Science ®Google Scholar
• Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med. 1980;302(25):1383–1389.
   PubMed Web of Science ®Google Scholar
• Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328(17):1220–1225.
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, Von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77(14):1179–1184.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276(11):882–888.
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213–219.
   PubMedGoogle Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,148 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–458.
   PubMed Web of Science ®Google Scholar
• Miller M, Stome NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–2333.
   PubMed Web of Science ®Google Scholar
• Harchaoui KE, Visser ME, Kastelein JJ, Stroes ES, Dallinga-thie GM. Triglycerides and cardiovascular risk. Curr Cardiol Rev. 2009;5(3):216–222.
   PubMedGoogle Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345–1361.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308.
   PubMed Web of Science ®Google Scholar
• Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309–316.
   PubMed Web of Science ®Google Scholar
• Ng M, Fleming T, Robisnon M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–781.
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169(6):572–578.
   PubMedGoogle Scholar
• Aguilar-Salinas CA, Olaiz G, Valles V, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001;42(8):1298–1307.
   Web of Science ®Google Scholar
• Wong McClure R, Leandra Abarca Gómez, Giselle Rovira Jiménez, et al. Vigilancia de los Factores de Riesgo Cardiovascular 2011. [Cardiovascular risk factor surveillance 2011]. Caja Costarricense de Seguro Social, Costa Rica. Spanish.
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, Sixth Edition. Brussels, Belgium: International Diabetes Federation, 2013. Available from: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed October 5, 2014.
   Google Scholar
• Genest JJ Jr, Martin-Munley SS, Mcnamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85(6):2025–2033.
   Web of Science ®Google Scholar
• Austin MA, Mcknight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation. 2000;101(24):2777–2782.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol. 2001;87(10):1174–1180.
   PubMed Web of Science ®Google Scholar
• Hopkins PN, Heiss G, Ellison C, et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia. A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation. 2003;108(5):519–523.
   Web of Science ®Google Scholar
• Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89(6):2601–2607.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. Atheroscler Suppl. 2004;5(3):91–97.
   PubMed Web of Science ®Google Scholar
• Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90(4):1679–1687.
   PubMed Web of Science ®Google Scholar
• Takayama T, Hiro T, Yamagishi M, et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease. Circ J. 2009;73(11):2120–2117.
   Web of Science ®Google Scholar
• Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101(5):477–484.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001–1009.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349–1357.
   Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007.
   PubMed Web of Science ®Google Scholar
• Packard CJ, Ford I, Robertson M, et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2005;112(20):3058–3065.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielsson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2105–2207.
   Web of Science ®Google Scholar
• [No authors listed]. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696.
   PubMed Web of Science ®Google Scholar
• Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368(9539):919–928.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   Web of Science ®Google Scholar
• Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
   Google Scholar
• Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104(25):3046–3051.
   PubMed Web of Science ®Google Scholar
• Mora S, Wenger NK, Demicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012;125(16):1979–1987.
   Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(Suppl 10):1K–34K.
   Google Scholar
• Brunzell JD, Davidson M, Furber CD, et al. Lipoprotein management in patients with cardiometabolic risk. Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15):1512–1524.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–2122.
   PubMed Web of Science ®Google Scholar
• AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267.
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group, Grinsberg HN, Elam MB, et al. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Expert Panel on detection evaluation and treatment of high cholesterol in adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497.
   Web of Science ®Google Scholar
• Grundy SM, Cleeman J I, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18 Suppl 1:1–78.
   Google Scholar
• Anderson TJ, Grégorie J, Hegele RA, et al. Society Guidelines 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2013;29(2):151–167.
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–1701.
   PubMed Web of Science ®Google Scholar
• Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. J Clin Lipidol. 2014;8(1):29–60.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–2934.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, Navar-Boggan AM, D’Agostino RB, et al. Application of new cholesterol guidelines to a population based-sample. N Engl J Med. 2014;370(15):1422–1431.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cook NR. Statins: the new American guidelines for prevention of cardiovascular disease. Lancet. 2014;382(9917):1762–1765.
   Google Scholar
• Brown MS, Goldstein JL. A receptor–mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34–47.
   PubMed Web of Science ®Google Scholar
• Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins – an integrated approach to mechanisms and disorders. N Engl J Med. 1967;276(1–5):34–281.
   Web of Science ®Google Scholar
• Ginsberg HN, Le NA, Golberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoprotein CIII and A I. Evidences that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78(5):1287–1290.
   PubMed Web of Science ®Google Scholar
• Chan DC, Watts GF. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin Pharmacother. 2011;12(1):13–30.
   PubMed Web of Science ®Google Scholar
• Oram JF, Vaughan AM. ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res. 2006;99(10):1031–1043.
   PubMed Web of Science ®Google Scholar
• Tall AR, Yan-Chavert L, Terasaka N, Pagle T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cel Metab. 2008;7(5):365–375.
   PubMed Web of Science ®Google Scholar
• Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968;9(2):155–167.
   PubMed Web of Science ®Google Scholar
• Agellon LB, Walsh A, Hayek T, et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem. 1991;266(17):10796–10801.
   Web of Science ®Google Scholar
• Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the gÉnesis of lesions of aterosclerosis. Science. 1973;180(4093):1332–1339.
   Google Scholar
• Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969–2989.
   PubMed Web of Science ®Google Scholar
• Handsson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
   Web of Science ®Google Scholar
• Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Ateroscler Thromb Vasc Biol. 1997;17(6):1011–1117.
   Web of Science ®Google Scholar
• Skålén K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417(6890):750–754.
   PubMed Web of Science ®Google Scholar
• Lamarche B, Tchernof A, Moorjni S, et al. Small, dense low-density lipoprotein particles as a predictior of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997;95(1):69–75.
   PubMed Web of Science ®Google Scholar
• Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidize LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest. 2009;119(1):136–145.
   Web of Science ®Google Scholar
• Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192(1):211–217.
   PubMed Web of Science ®Google Scholar
• Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoproteins subclass patterns and risk of myocardial infarction. JAMA. 1998;260(13):1917–1921.
   Google Scholar
• Ginsberg HN. New perspectives on atherogenesis: Role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002;106(16):2137–2142.
   Web of Science ®Google Scholar
• Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb. 1994;14(11):1767–1774.
   PubMedGoogle Scholar
• Daugherty A, Lange LG, Sobel BE, Schonfeld G. Aortic accumulation and plasma clearance of b-VLDL and HDL: effects of diet-induced hypercholesterolemia in rabbits. J Lipid Res. 1985;26(8):955–963.
   Web of Science ®Google Scholar
• Proctor SD, Mamo JC. Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall – evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest. 1998;28(6):497–503.
   Web of Science ®Google Scholar
• Goldstein JL, Ho YK, Brown MS, Innerarity TL, Mahley RW. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. J Biol Chem. 1980;255(5):1839–1848.
   Web of Science ®Google Scholar
• Pitas RE, Innerarity TL, Mahley RW. Foam cells in explants of atherosclerotic rabbit aortas have receptors for beta-very low density lipoproteins and modified low density lipoproteins. Arteriosclerosis. 1983;3(1):2–12.
   Google Scholar
• Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 1997;17(4):715–722.
   PubMed Web of Science ®Google Scholar
• Grønholdt ML, Nordestgaard BG, Nielsen TG, Sillesen H. Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke. 1996;27(12):2166–2172.
   PubMed Web of Science ®Google Scholar
• Austin MA, King KM, Vrannizanm KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82(2):495–506.
   PubMed Web of Science ®Google Scholar
• Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, Crouse JR. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke. 1992;23(6):823–828.
   Web of Science ®Google Scholar
• Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 1995;15(12):2122–2129.
   Web of Science ®Google Scholar
• Meyer E, Westerveld HE, De Ruijter-Heijstek FC, et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: A case-control study. Atherosclerosis. 1996;124(2):221–235.
   Web of Science ®Google Scholar
• Karpe F, de Faire U, Mercuri M, Bond MG, et al. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclerosis. 1998;141(2):307–314.
   Web of Science ®Google Scholar
• Cromwell WC, Otvos JD, Keyes MJ, et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study – Implications for LDL Management. J Clin Lipidol. 2007;1(6):583–1592.
   PubMed Web of Science ®Google Scholar
• Zaman GS, Rahman S, Rahman J. Postprandial lipemia in pre- and postmenopausal women. J Nat Sci Biol Med. 2012;3(1):65–70.
   Google Scholar
• Giannattasio C, Zoppo A, Gentile G, et al. Acute effect of high-fat meal on endothelial function in moderately dyslipidemic subjects. Arterioscler Thromb Vasc Biol. 2005;25(2):406–410.
   Web of Science ®Google Scholar
• Moyer MP, Tracy RP, Tracy PB, van’t Veer C, Sparks CE, Mann KG. Plasma lipo-proteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol. 1998;18(3):458–465.
   Web of Science ®Google Scholar
• Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342(24):1792–1801.
   PubMed Web of Science ®Google Scholar
• Murphy AJ, Woollard KJ, Hoang A, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008;28(11):2071–2077.
   PubMed Web of Science ®Google Scholar
• Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98(11):1352–1364.
   PubMed Web of Science ®Google Scholar
• Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol. 2010;23(3):447–454.
   Web of Science ®Google Scholar
• The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. N Engl J Med. 2014;371(1):22–31.
   Google Scholar
• Sievenpiper JL, do Souza RJ, Cozma AI, Chiavarilo L, Ha V, Mirrahimi A. Fructose vs Glucose and metabolism: do the metabolic differences matter? Curr Opin Lipidol. 2014;25(1):8–19.
   Web of Science ®Google Scholar
• King AC, Haskell WL, Young DR, Oka RK, Stefanick ML. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness and lipoproteins in men and women aged 50 to 65 years. Circulation. 1995;91(10):2596–2604.
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088–2093.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Brewer HB Jr, Leitersdorg E. Consensus of the use of fibrates in the treatment of dyslipidemia and coronary heart disease. Fibrates Consensus Group. Am J Cardiol. 1998;81(7):912–917.
   Web of Science ®Google Scholar
• Rader DJ, Haffner SM. Role of fibrates in the management of hypertriglyceridemia. Am J Cardiol. 1999;83(9B):30F–35F.
   Web of Science ®Google Scholar
• Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res and Opin. 2002;18(5):269–276.
   PubMed Web of Science ®Google Scholar
• Jones PH, Pownall HJ, Patsch W, et al. Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects. J Lipid Res. 1996;37(6):1298–1308.
   Web of Science ®Google Scholar
• Dierkes J, Westphal S, Luley C. Fenofibrate-induced hyperhomocystenemia clinical Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vasc Health Risk Manag. 2008;4(5):991–1000.
   Google Scholar
• Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res. 1990;31(4):567–582.
   Web of Science ®Google Scholar
• Conde K, Vergara-jimenez M, Krause BR, Newton RS, Fernandez ML. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res. 1996;37(11):2372–2382.
   Web of Science ®Google Scholar
• Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys. 1996;325(2):242–248.
   Web of Science ®Google Scholar
• Ness GC, Chambers CM, Lopez D. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity. J Lipid Res. 1998;39(1):75–84.
   Web of Science ®Google Scholar
• Jones PH, Davidson MH. Reporting rate of rhabdomyolisis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95(1):120–122.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Pradhan A, Macfadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–571.
   PubMed Web of Science ®Google Scholar
• Carter AA, Gomes T, Camacho X, Jurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.
   PubMed Web of Science ®Google Scholar
• Dormuth CT, Filion KB, Paterson JM, et al. Higher potency statins and the risk of new diabetes: multicenter observational study of administrative databases. BJM. 2014;48:g3244.
   Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–1245.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–418.
   PubMed Web of Science ®Google Scholar
• The Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raisin HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21–27.
   Web of Science ®Google Scholar
• [No authors listed]. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, A randomized Study. Lancet. 2001;357(9260):905–910.
   Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
   PubMed Web of Science ®Google Scholar
• Ting RD, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012;35(2):218–225.
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875–1884.
   PubMed Web of Science ®Google Scholar
• Study of the effectiveness of additional reduction in cholesterol and homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomized trial. Lancet. 2010;376(9753):1658–1669.
   Web of Science ®Google Scholar
• Rosen JB, Jimenez JG, Pirags V, et al. Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects. Lipids Health Dis. 2013;12(1):103.
   Google Scholar
• Nakajima N, Miyauchi K, Yokoyama T, et al. Effect of combination of ezetimibe and statin on coronary plaque regression in patients with acute coronary syndrome ZEUS trial (eZEtimibe Ultrasound Study). IJC Metabolic and Endocrine. 2014;3:8–13.
   Google Scholar
• Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovascular Diabetology. 2012; 11:125:1–10.
   Web of Science ®Google Scholar
• Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundamental and Clinical Pharmacology. 2010;24(1):19–28.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patient: A clinical update. Nutrition, Metabolism and Cardiovascular Disease. 2013;23(9):799–807.
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol. 2004;44(9):1054–1062.
   PubMed Web of Science ®Google Scholar
• Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis. 1996;7(11):843–850.
   Web of Science ®Google Scholar
• Shah HD, Parikh KH, Chag MC, et al. Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. Exp Clin Cardiol. 2007;12(2):91–96.
   Google Scholar
• Ooi T, Heinone T, Alaupovic P, et al. Efficacy and safety of a new hydroximethyglutary-Coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia:comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 1997;17(9):1793–1799.
   Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997;80(5):608–613.
   PubMed Web of Science ®Google Scholar
• Kirchgässler KU, Schiffner-rohe J, Stahlheber U. Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia. Pharmacoeconomics. 1997;12(2 Pt 2):237–246.
   Web of Science ®Google Scholar
• Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 1998;81(4A):60B–65B.
   PubMed Web of Science ®Google Scholar
• Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J. 1999;138(1 Pt 1):151–155.
   Web of Science ®Google Scholar
• Weinstein DL, Williams LA, Carslon DM, et al. A Randomized, Double-Blind Study of Fenofibric Acid Plus Rosuvastatin Compared With Rosuvastatin Alone in Stage 3 Chronic Kidney Disease. Clin Ther. 2013;35;(8):1186–1198.
   Web of Science ®Google Scholar
• Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailidis DP. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol. 1999;69(3):237–244.
   PubMed Web of Science ®Google Scholar
• Spieker LE, Noll G, Hannak M, Luscher TF. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. J Cardiovasc Pharmacol. 2000;35(3):361–365.
   PubMed Web of Science ®Google Scholar
• Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med. 2000;247(5):563–569.
   PubMed Web of Science ®Google Scholar
• Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006;48(2):396–401.
   Web of Science ®Google Scholar
• Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35(7–8):908–917.
   PubMed Web of Science ®Google Scholar
• Wilmink HW, Twickler MB, Banga JD, et al. Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles. Cardiovasc Res. 2001;50(3):577–582.
   PubMed Web of Science ®Google Scholar
• Kayikciogly M, Ozerkan F, Soydan I. Effectiveness and safety of alternative-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol. 1999;83(7):1135–1137.
   Web of Science ®Google Scholar
• Chan SY, Mancini GBJ, Ignszewski A, Frolich J. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study. BMC Clinical Pharmacology. 2008;8:10.
   PubMedGoogle Scholar
• Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009;103(4):515–522.
   PubMed Web of Science ®Google Scholar
• Ansquer JC, Corda C, Le Malicot K, Jessent V. Effects of atorvastatin 120 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: a 12 week, multicentric, randomized, open-label, parallel group study. Curr Ther Res Clin Exp. 2009;70(2):71–93.
   Web of Science ®Google Scholar
• Yang LP, Keating GM. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. Am J Cardiovasc Drugs. 2009;9(6):401–409.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Karagiannis A, Mikhaiidis DP. Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia. Am J Cardiol. 2008;101(11):1679–1680.
   Web of Science ®Google Scholar
• Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol. 2003;91(8):956–960.
   Web of Science ®Google Scholar
• Stefanutti C, Bucci A, Di Giacomo S, et al. Efficacy, safety and tolerability of combined-low dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. Clin Drug Investig. 2004;24(8):465–477.
   Web of Science ®Google Scholar
• Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95(4):462–468.
   PubMed Web of Science ®Google Scholar
• May HT, Anderson JL, Pearson RR, et al. Comparison of the effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipid subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol. 2008;101(4):486–489.
   Web of Science ®Google Scholar
• Bays HE, Jones PH, Mohiuddin SM, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol. 2008;2(6):426–435.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin. 2009;25(8):1973–1983.
   PubMed Web of Science ®Google Scholar
• Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009;157(1):195–203.
   Web of Science ®Google Scholar
• Jones PH, Cusi K, Davidson MH, et al. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010;10(2):73–84.
   Web of Science ®Google Scholar
• Farnier M, Steinmetz A, Rettersol K, Csaszar A. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Clin Ther. 2011;33(1):1–12.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12(12):1945–1958.
   PubMed Web of Science ®Google Scholar
• Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122(8):850–852.
   PubMed Web of Science ®Google Scholar
• Karbasi-Afshar R, Shahmari A, Saburi A. Echocardiographic and exercise test findings in patients with dyslipidemia and coronary artery disease before and after treatment with simvastatin with or without fenofibrate. Int Cardiovas Res J. 2011;5(4):143–147.
   Google Scholar
• Davidson MH, Rosenson RS, Maki KC, et al. Effects of fenofibric acid on carotid Intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomised placebo, controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014;34(6):1298–1306.
   Web of Science ®Google Scholar
• Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007;30(8):1945–1951.
   PubMed Web of Science ®Google Scholar
• Reyes-Soffer G, Ngai CI, Lovato L, et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care. 2013;36(2):422–428.
   Web of Science ®Google Scholar
• Koval’O. Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome. Available from: http://ClinicalTrials.gov/show/NCT02015988. NLM identifier: NCT02015988. Accessed October 5, 2014.
   Google Scholar